SCHEMBL2244261

SCHEMBL2244261

O=S(=O)(O)CCN(CCO)CCO.[NaH]

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.36
PDE4A P27815 1/20 0.36
LMNA P02545 1/20 0.36
SLC6A6 P31641 1/20 0.36
CYP2C19 P33261 1/20 0.36
BLM P54132 1/20 0.36
APP P05067 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99322 0.97 PTGS1 (0.38) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL7622762 0.97 PTGS1 (0.38) PTGS1PDE4ALMNASLC6A6CYP2C19
Ammonia Solution, Strong SCHEMBL3903413 0.95 PTGS1 (0.36) PTGS1PDE4ALMNASLC6A6CYP2C19
Hydrochloric Acid SCHEMBL1336339 0.95 PTGS1 (0.36) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL9898850 0.95 PTGS1 (0.36) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL9898366 0.95 PTGS1 (0.36) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL29419676 0.95 PTGS1 (0.36) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL11237951 0.89 APP (0.39) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL22056603 0.89 APP (0.34) PTGS1PDE4ALMNASLC6A6CYP2C19
SCHEMBL18269185 0.87 CA1 (0.34) PTGS1PDE4ALMNASLC6A6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220226325-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN (AR) 2022-07-21 US claimed
EP-4025562-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) (AR) 2022-07-13 EP claimed
WO-2021046290-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (AR) 2021-03-11 WO claimed
US-4563291-A Method of preparation of substituted amino-alkyl sulfonic acid compounds and use in the treatment of subterranean formations HALLIBURTON COMPANY (US) 1986-01-07 US claimed
WO-2023141721-A1 ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS UNIVERSITY OF MONTRÉAL (CA) 2023-08-03 WO disclosed
WO-2023147489-A2 ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS argenx BV (BE) 2023-08-03 WO disclosed
US-20220226325-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN (AR) 2022-07-21 US disclosed
EP-4025562-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) (AR) 2022-07-13 EP disclosed
US-11382913-B2 Pharmaceutical composition for topical wound treatment CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (AR) 2022-07-12 US disclosed
WO-2021046290-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (AR) 2021-03-11 WO disclosed
US-9612204-B2 Measurement of scale inhibitor in water systems CONOCOPHILLIPS COMPANY (US) 2017-04-04 US disclosed
US-20160349186-A1 MEASUREMENT OF SCALE INHIBITOR IN WATER SYSTEMS CONOCOPHILLIPS COMPANY 2016-12-01 US disclosed
WO-2009085809-A1 IONOMERS FOR IMPROVED COMPRESSION SET IN CERTAIN COPOLYMERS THE POLYMER TECHNOLOGY GROUP INC. (US) 2009-07-09 WO disclosed
US-20090087687-A1 SULFONIC ACID POLYOL COMPOUND, POLYURETHANE RESIN, POLYURETHANE RESIN FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM FUJIFILM CORPORATION (JP) 2009-04-02 US disclosed
US-20040241348-A1 Recording paper, and image recording method and device using the same FUJI XEROX CO., LTD. (JP) 2004-12-02 US disclosed
EP-0406334-A4 HYDROGEL DYE FILM SENSING ELEMENTS AND THEIR PREPARATION 1991-11-13 EP disclosed
EP-0406334-A1 HYDROGEL DYE FILM SENSING ELEMENTS AND THEIR PREPARATION NELLCOR INCORPORATED (US) 1991-01-09 EP disclosed
WO-1990000572-A1 HYDROGEL DYE FILM SENSING ELEMENTS AND THEIR PREPARATION NELLCOR INCORPORATED (US) 1990-01-25 WO disclosed
EP-0169074-A2 Treatment of subterranean formations HALLIBURTON COMPANY (US) 1986-01-22 EP disclosed
US-4563291-A Method of preparation of substituted amino-alkyl sulfonic acid compounds and use in the treatment of subterranean formations HALLIBURTON COMPANY (US) 1986-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090087687-A1 SULFONIC ACID POLYOL COMPOUND, POLYURETHANE RESIN, POLYURETHANE RESIN FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM ASH2L, ASIC1, HNRNPL PTGS1 702/4885PDE4A 4801/4885LMNA 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.